SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Businessman looks at the rugged road
Obesity
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
AbbVie’s foray into the obesity space is successful so far, analysts agree, as amylin analog ABBV-295 elicited as much as 9.73% weight loss at 13 weeks in the multiple ascending dose portion of a Phase 1 trial.
March 9, 2026
 · 
2 min read
 · 
Heather McKenzie
Cooperation concept. Vector of a businessman and a businesswoman connecting the bridge with a missing part
GLP-1s
Novo Nordisk Agrees To Sell GLP-1 Drugs Via Hims & Hers, Ending Dispute
The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that could increase access to Novo’s obesity medicines.
March 9, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Business team conducts rowing competition
Weight loss
Regeneron’s Weight Loss Partner Hansoh Delivers Much-Needed Phase 3 Win in China
Hansoh’s olatorepatide achieved 19% weight loss at 48 weeks in a Phase 3 trial in China, handing partner Regeneron a glimmer of hope for a pipeline in desperate need of reinvigoration.
March 9, 2026
 · 
2 min read
 · 
Annalee Armstrong
Vertical collage image of black white effect arm hold tied arrow shoot down darts board target isolated on painted background.
Breast cancer
Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall
Roche’s shares tumbled nearly 5% on news that a key pillar in the five-pronged clinical plan for the breast cancer asset giredestrant was unsuccessful.
March 9, 2026
 · 
2 min read
 · 
Annalee Armstrong
Drug Development
Xenon To Seek Approval of First-in-Class Epilepsy Drug After Exceeding Phase 3 Expectations
Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7%. Xenon Pharmaceuticals believes this is the highest such efficacy “observed in a pivotal epilepsy study,” CEO Ian Mortimer said Monday.
March 9, 2026
 · 
3 min read
 · 
Heather McKenzie
Dashed line from pills isolated on white
Cancer
Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies
Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated safety risk in patients undergoing treatment.
March 9, 2026
 · 
2 min read
 · 
Tristan Manalac
Background with halftone hand hold magnifier and torn papers. Collage element for search concept. Find information in internet browser.
Adcomms
Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months
The FDA’s cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT inhibitor Truqap in prostate cancer.
March 9, 2026
 · 
3 min read
 · 
Tristan Manalac
The white plane flies against the blue sky, leaving a white trail. Vector illustration
Rare diseases
Prasad’s Departure Could Be ‘Big Win’ for Biotech—Especially Rare Disease Space: Analysts
Some biotechs that had seen regulatory setbacks under Center for Biologics Evaluation and Research director Vinay Prasad experienced stock bumps Monday morning. Under Prasad’s leadership, the rare disease space has suffered a series of controversial rejections.
March 9, 2026
 · 
3 min read
 · 
Tristan Manalac
halftone magazine style banner, dislike, negative rating, hand thumbs down
Complete response letters
Incyte’s Lung Cancer Expansion Bid Thwarted by Issues at Novo’s Catalent-Acquired Site
Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did not flag problems with the drug’s efficacy or safety.
March 9, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS